International Lung Cancer Consortium: pooled analysis of sequence variants in DNA repair and cell cycle pathways - PubMed (original) (raw)

Multicenter Study

. 2008 Nov;17(11):3081-9.

doi: 10.1158/1055-9965.EPI-08-0411.

David C Christiani, Angela Risch, Odilia Popanda, Aage Haugen, Shan Zienolddiny, Simone Benhamou, Christine Bouchardy, Qing Lan, Margaret R Spitz, H-Erich Wichmann, Loic LeMarchand, Paolo Vineis, Giuseppe Matullo, Chikako Kiyohara, Zuo-Feng Zhang, Benhnaz Pezeshki, Curtis Harris, Leah Mechanic, Adeline Seow, Daniel P K Ng, Neonila Szeszenia-Dabrowska, David Zaridze, Jolanta Lissowska, Peter Rudnai, Eleonora Fabianova, Dana Mates, Lenka Foretova, Vladimir Janout, Vladimir Bencko, Neil Caporaso, Chu Chen, Eric J Duell, Gary Goodman, John K Field, Richard S Houlston, Yun-Chul Hong, Maria Teresa Landi, Philip Lazarus, Joshua Muscat, John McLaughlin, Ann G Schwartz, Hongbing Shen, Isabelle Stucker, Kazuo Tajima, Keitaro Matsuo, Michael Thun, Ping Yang, John Wiencke, Angeline S Andrew, Stephanie Monnier, Paolo Boffetta, Paul Brennan

Affiliations

Multicenter Study

International Lung Cancer Consortium: pooled analysis of sequence variants in DNA repair and cell cycle pathways

Rayjean J Hung et al. Cancer Epidemiol Biomarkers Prev. 2008 Nov.

Abstract

Background: The International Lung Cancer Consortium was established in 2004. To clarify the role of DNA repair genes in lung cancer susceptibility, we conducted a pooled analysis of genetic variants in DNA repair pathways, whose associations have been investigated by at least 3 individual studies.

Methods: Data from 14 studies were pooled for 18 sequence variants in 12 DNA repair genes, including APEX1, OGG1, XRCC1, XRCC2, XRCC3, ERCC1, XPD, XPF, XPG, XPA, MGMT, and TP53. The total number of subjects included in the analysis for each variant ranged from 2,073 to 13,955 subjects.

Results: Four of the variants were found to be weakly associated with lung cancer risk with borderline significance: these were XRCC3 T241M [heterozygote odds ratio (OR), 0.89; 95% confidence interval (95% CI), 0.79-0.99 and homozygote OR, 0.84; 95% CI, 0.71-1.00] based on 3,467 cases and 5,021 controls from 8 studies, XPD K751Q (heterozygote OR, 0.99; 95% CI, 0.89-1.10 and homozygote OR, 1.19; 95% CI, 1.02-1.39) based on 6,463 cases and 6,603 controls from 9 studies, and TP53 R72P (heterozygote OR, 1.14; 95% CI, 1.00-1.29 and homozygote OR, 1.20; 95% CI, 1.02-1.42) based on 3,610 cases and 5,293 controls from 6 studies. OGG1 S326C homozygote was suggested to be associated with lung cancer risk in Caucasians (homozygote OR, 1.34; 95% CI, 1.01-1.79) based on 2,569 cases and 4,178 controls from 4 studies but not in Asians. The other 14 variants did not exhibit main effects on lung cancer risk.

Discussion: In addition to data pooling, future priorities of International Lung Cancer Consortium include coordinated genotyping and multistage validation for ongoing genome-wide association studies.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Study-specific estimates and summary OR for XRCC3 T241M and TP53 R72P.

References

    1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. Lyon: IARC Press; 2004.
    1. Peto R, Darby S, Deo H, et al. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ. 2000;321:323–9. - PMC - PubMed
    1. Boffetta P, Trichopoulos D. Cancer of the lung, larynx, and pleura. In: Adami HO, Hunter D, Trichopoulos D, editors. Text book of cancer epidemiology. New York: Oxford University Press; 2002. pp. 248–80.
    1. Boffetta P, Armstrong B, Linet M, et al. Consortia in cancer epidemiology: lessons from InterLymph. Cancer Epidemiol Bio-markers Prev. 2007;16:197–9. - PubMed
    1. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature. 2001;411:366–74. - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources